MK2 Inhibitor and CRISPR Cas9 for Leukemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for leukemia lack effective prophylactic and therapeutic options that specifically target leukemogenesis, particularly for pre-leukemia conditions such as congenital neutropenia and myelodysplastic syndrome, which often progress to acute myeloid leukemia (AML), and existing MK2 inhibitors have shown limited activity when used alone.
Innovation Solution
The development of an MK2 inhibitor, specifically CMPD1, which selectively inhibits the activity of mitogen-activated protein kinase-activated protein kinase 2 (MK2), and a pharmaceutical composition comprising this inhibitor for use in treating and preventing leukemia, including AML, by targeting the p38 MAPK/MK2 signaling pathway and reducing BAALC expression through CRISPR/Cas9-mediated gene editing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing MK2 inhibitors are used alone, then some inhibition activity is achieved, but the therapeutic effect is limited and insufficient
Solution Approach 1:
The patent combines MK2 inhibition with CRISPR/Cas9-mediated BAALC gene knockout to achieve synergistic anti-leukemia effects. This dual approach merges pharmacological inhibition with genetic modification, overcoming the limited efficacy of MK2 inhibitors used alone and providing reliable therapeutic outcomes for leukemia treatment
2Adaptability or versatility
If conventional leukemia treatments are applied, then general treatment is provided, but specific targeting of leukemogenesis is lacking
Solution Approach 1:
The patent employs local quality by specifically targeting the BAALC gene and MK2 pathway in leukemia cells through CRISPR/Cas9 and MK2 inhibitors. This localized targeted approach distinguishes leukemia cells from normal cells, providing both specific targeting and reliable prophylactic/therapeutic effectiveness without affecting healthy tissues
3Reliability
If pre-leukemia conditions are left untreated, then natural progression occurs, but development to AML is prevented by early intervention
Solution Approach 1:
The patent applies preliminary action by using MK2 inhibitors and CRISPR/Cas9 to target BAALC expression in pre-leukemia conditions before full AML development occurs. This early intervention prevents disease progression to AML, demonstrating reliable prophylaxis effectiveness while minimizing the time window for disease development
Data Source
AI summary
The invention is directed to a compound for use in the prophylaxis and/or treatment of leukemia and/or the development of leukemia, a pharmaceutical composition for the prophylaxis and/or treatment of leukemia and/or the development of leukemia, comprising said compound, a method for the prophylaxis and/or treatment of leukemia and/or the development of leukemia in a living being, a single guide RNA (sgRNA) molecule which can be used in the method according to the invention.